Literature DB >> 3990336

Relationship between the intracellular level and growth inhibition of a new anthracycline 4'O-tetrahydropyranyl-Adriamycin in Friend leukemia cell variants.

J N Munck, A Fourcade, M Bennoun, H Tapiero.   

Abstract

The relationship between the intracellular amount of a new anthracycline derivative, 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) and its cytotoxic activity in Friend leukemia cells (FLC) was investigated. By comparison to adriamycin (ADM), the uptake of THP-ADM is a very rapid process reaching maximal levels within 5 min. Both drugs are accumulated and retained in the nuclear fraction. The two main consequences associated to these different uptake rate are: following short-time cell exposure to comparable drug concentration, the higher cytotoxic effect of THP-ADM correlates to the ease with which it crosses the cell membrane; the intracellular amount of THP-ADM but not of ADM decreases with the cell density. These results emphasize the importance of considering drug uptake kinetics and its relationship to cytotoxicity. Studies comparing uptake and efflux of both drugs in ADM-resistant cells showed that THP-ADM extrusion correlate more to cytotoxicity than that of ADM. The relevance of these in vitro findings to clinical application is considered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3990336     DOI: 10.1016/0145-2126(85)90091-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.

Authors:  Hiroki Hori; Tooru Kudoh; Shinichiro Nishimura; Megumi Oda; Makoto Yoshida; Junichi Hara; Akio Tawa; Ikuya Usami; Akihiko Tanizawa; Keiko Yumura-Yagi; Koji Kato; Ryoji Kobayashi; Yoshihiro Komada; Keitaro Matsuo; Keizo Horibe
Journal:  Int J Clin Oncol       Date:  2016-11-17       Impact factor: 3.402

2.  A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.

Authors:  D Marchiset-Leca; F R Leca; A Galeani; A Noble; A Iliadis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.

Authors:  J Robert; A Monnier; N Poutignat; P Hérait
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases.

Authors:  L H Ramirez; J N Munck; C Bognel; Z Zhao; P Ardouin; M F Poupon; A Gouyette; P Rougier
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.